Gastroesophageal Reflux Disease Management

Pharmacological Interventions

• The FDA notes that H2 blockers or antacids are appropriate alternatives when immediate symptom relief is needed, according to the American Heart Association guidelines 1
• H. pylori eradication can be achieved with twice daily dosing of H2-receptor antagonists as part of combination therapy, as recommended by the American Gastroenterological Association 2
• Proton pump inhibitors (PPIs) are the cornerstone of treatment for gastroesophageal reflux disease (GERD) management, due to their superior efficacy in acid suppression, with standard dosing including omeprazole 20mg, lansoprazole 30mg, or pantoprazole 40mg once daily before a meal, as recommended by the American Gastroenterological Association 3
• Conditions that may require PPI therapy include Barrett's esophagus, severe erosive esophagitis, and high risk for GI bleeding, as noted by the American College of Gastroenterology 4, 5
• Patients with Eosinophilic esophagitis (EoE) who have responded to initial PPI treatment may require maintenance therapy, as recommended by the American Gastroenterological Association and the British Society of Gastroenterology 6
• The use of PPIs can decrease the solubility of some direct-acting antivirals (DAAs) like glecaprevir, used in hepatitis C medications, according to the European Association for the Study of the Liver 7
• PPIs may interact with other medications, such as clopidogrel, and patients should be monitored for potential interactions, as recommended by the American College of Cardiology 8
• Potassium-Competitive Acid Blockers (P-CABs) may provide more potent acid inhibition than PPIs and may be considered in selected patients with documented acid-related reflux who fail therapy with twice-daily PPIs 3
• H2-Receptor Antagonists (H2RAs) are less effective than PPIs but may be considered in selected patients, although they are not recommended as maintenance therapy in patients with previous erosive esophagitis 9

Diagnostic Testing

• Ambulatory pH monitoring, preferably 96-hour wireless pH monitoring off medication, helps confirm and phenotype GERD or rule it out, as suggested by the American Gastroenterological Association 10
• Combined pH-Impedance monitoring is particularly useful if non-acid reflux is suspected and can be performed while on PPI therapy to evaluate ongoing reflux, as recommended by the American Gastroenterological Association 11, 12
• Upper endoscopy should include multiple biopsies from different levels of the esophagus, with specific evaluation for erosive esophagitis, Barrett's esophagus, eosinophilic esophagitis, and assessment of hiatal hernia, as recommended by the American Gastroenterological Association 10

Discontinuation and Side Effects

• When discontinuing PPIs, patients may experience rebound acid hypersecretion due to increased parietal cell mass and enhanced capacity to produce acid once the inhibitory effect of PPIs is removed 4
• A gradual tapering approach is recommended to minimize rebound acid hypersecretion and associated symptoms, starting with a reduction from 40 mg daily to 20 mg daily, maintaining this dose for 2-4 weeks, and monitoring for symptom recurrence, as recommended by the European Society of Gastrointestinal Endoscopy and the American Gastroenterological Association 13, 4, 6
• Long-term PPI use may lead to malabsorption of vitamin B12, iron deficiency, and increased risk of fractures, hypomagnesemia, and acute tubulointerstitial nephritis, prompting consideration of monitoring and careful evaluation in elderly patients and those with pre-existing malabsorption, as recommended by the American Gastroenterological Association 14, 4, 5